Active — Not RecruitingNot Applicable

Photobiomodulation Therapy for Scar Quality After Facial Wound Closure

Iraq36 participantsStarted 2024-10-17

Plain-language summary

This study is a prospective pilot randomized controlled trial designed to evaluate the effect of photobiomodulation therapy (PBMT) on scar quality following traumatic facial wound closure. Traumatic facial wounds often result in aesthetically and functionally significant scars, which may negatively affect patients' quality of life. PBMT has been proposed as a non-invasive adjunctive therapy that may enhance tissue repair, reduce inflammation, and improve scar outcomes. In this study, patients with traumatic facial wounds undergoing primary closure will be randomly assigned to receive either PBMT or sham treatment following suture removal. Scar quality will be assessed using validated clinical scales over a defined follow-up period. The findings of this study aim to provide clinical evidence regarding the effectiveness of PBMT in improving scar appearance and overall healing outcomes.

Who can participate

Age range13 Years – 47 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients presenting with traumatic facial wounds requiring primary closure with sutures. * Superficial to partial-thickness wounds located in the facial region (including infraorbital/periorbital, cheek, chin, forehead, or perioral areas). * Wound length ranging from 3.5 to 10 cm. * Patients willing to participate and comply with all treatment sessions and follow-up visits. * Written informed consent obtained from adult participants or from parents/legal guardians for participants under 18 years of age. Exclusion Criteria: * Patients with uncontrolled systemic diseases that may impair wound healing (e.g., uncontrolled diabetes, immunocompromised conditions). * Patients receiving medications known to affect wound healing (e.g., corticosteroids, immunosuppressive drugs). * Presence of infected wounds at baseline. * Patients with a history of keloid or hypertrophic scar formation. * Pregnant or lactating women. * Patients who are unable or unwilling to comply with the study protocol or follow-up schedule.

What they're measuring

Scar Quality Assessed by POSAS

Timeframe: 3 months and 12 months after completion of treatment

Trial details

NCT IDNCT07523204

SponsorHani M. Al-Kufi

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10-07